BioNTech (NASDAQ:BNTX) Price Target Lowered to $130.00 at Citigroup

BioNTech (NASDAQ:BNTX) had its price objective lowered by Citigroup from $145.00 to $130.00 in a research report released on Wednesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other equities research analysts have also commented on the company. TD Cowen cut their price objective on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research note on Wednesday. Morgan Stanley decreased their target price on BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a research note on Tuesday. The Goldman Sachs Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday. Finally, Bank of America restated a “buy” rating and issued a $128.00 price objective on shares of BioNTech in a report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Stock Up 8.3%

BNTX stock opened at $90.84 on Wednesday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $106.64 and a 200-day simple moving average of $102.75. The stock has a market capitalization of $20.46 billion, a P/E ratio of -17.34 and a beta of 1.51.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhenman & Partners Asset Management AB boosted its stake in BioNTech by 0.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after buying an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of BioNTech by 0.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after acquiring an additional 127 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. Probity Advisors Inc. raised its holdings in shares of BioNTech by 5.7% during the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after acquiring an additional 135 shares during the period. Finally, Profund Advisors LLC boosted its position in shares of BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after acquiring an additional 149 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS -$0.39 vs -$0.57 expected; revenue ~$1.06B vs $942M expected); management highlighted a strong cash position and multiple upcoming late‑stage readouts. Earnings Press Release
• Positive Sentiment: Analysts remain generally constructive: Canaccord reaffirmed a Buy with a $171 PT and Goldman Sachs also reaffirmed Buy — these positive analyst stances can support near‑term buying interest. Canaccord Note
• Neutral Sentiment: BioNTech announced plans to contribute certain rights/technologies to a new independent company led by co‑founders; BioNTech will retain a minority stake and may receive milestones/royalties — could free focus/resources but adds execution complexity. Company Release
• Neutral Sentiment: Reported short‑interest data in March shows zero shares (likely a reporting/data anomaly) — not meaningful for sentiment at this time.
• Negative Sentiment: Co‑founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to leave by end of 2026 to launch a new mRNA company — markets view founder exits as a governance and execution risk, which triggered heavy selling. Reuters
• Negative Sentiment: FY‑2026 revenue guidance was lowered materially (company now sees ~€2.0–2.3B vs consensus nearer €3.1B) — the weaker outlook is a primary driver of the recent selloff. Full Results & Guidance
• Negative Sentiment: Multiple outlets reported a steep one‑day stock drop after the earnings/guidance and founder news; several brokers have cut price targets (Jefferies, Citigroup, BMO lowered PTs; TD Cowen moved to Hold) — analyst downgrades/PT cuts amplify downside pressure. Analyst Notes Summary
• Negative Sentiment: Investor litigation/claims firm Johnson Fistel announced an inquiry into potential shareholder claims related to executive actions — adds legal/ reputational overhang. Johnson Fistel Notice

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.